Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Venous Thromboembolism 7Venous Thrombosis 5Pulmonary Embolism 4Neoplasms 4Thromboembolism 2Lung Neoplasms 2Thrombosis 1Thrombocytopenia 1Pancreatic Neoplasms 1Multiple Myeloma 1Lymphoma 1Liver Neoplasms 1Kidney Neoplasms 1Hemorrhage 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Renal Cell 1Carcinoma, Ovarian Epithelial 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1

Interventions

aldesleukin 42Sunitinib 39Cyclophosphamide 30Nivolumab 27Everolimus 27pembrolizumab 26Interferon-alpha 25Bevacizumab 22Sorafenib 21Interleukin-2 20fludarabine phosphate 19Filgrastim 18Ipilimumab 17Radiotherapy 16Axitinib 16Peripheral Blood Stem Cell Transplantation 15Gemcitabine 15cabozantinib 14fludarabine 11Radiosurgery 11Doxorubicin 11Carboplatin 11temsirolimus 10Etoposide 9Chemotherapy, Adjuvant 9sargramostim 8belzutifan 8atezolizumab 8Fluorouracil 8pazopanib 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Kidney Neoplasms × Tinzaparin × Clear all
NCT00293501 2013-11-06

Tinzaparin in Treating Patients With Metastatic Kidney Cancer That Cannot Be Removed By Surgery

National Cancer Institute (NCI)

Phase 1/2 Unknown
35 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡